3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Prostatic Neoplasms
3
Lung Neoplasms
2
Disease
2
Colorectal Neoplasms
2
Acute Kidney Injury
2
Urinary Bladder Neoplasms
1
Tuberous Sclerosis
1
Smoldering Multiple Myeloma
1
Salivary Gland Adenoma, Pleomorphic
1
Renal Insufficiency
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Monoclonal Gammopathy of Undetermined Significance
1
Lymphangioleiomyomatosis
1
Kidney Neoplasms
1
Hemangiosarcoma
1
Glioma
1
Gallbladder Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Pancreatic Ductal
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Paclitaxel
7
Doxorubicin
5
pembrolizumab
4
pazopanib
4
Gemcitabine
4
Bevacizumab
4
durvalumab
3
Radiotherapy
3
Propranolol
3
Docetaxel
3
regorafenib
2
cemiplimab
2
Surveys and Questionnaires
2
Sunitinib
2
Standard of Care
2
Nivolumab
2
Ifosfamide
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
tremelimumab
1
trebananib
1
trastuzumab duocarmazine
1
talimogene laherparepvec
1
talazoparib
1
spartalizumab
1
sintilimab
1
selinexor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Hemangiosarcoma
×
Urination
×
Clear all
NCT01786889
2016-07-29
ANGIHE
Centre Oscar Lambret
Phase NA
Unknown
9 enrolled